Novel WWP2 ubiquitin ligase isoforms as potential prognostic markers and molecular targets in cancer

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 12, 2013, Pages 2127-2135

  Soond, Surinder M ^a   Smith, Paul G ^a   Wahl, Lloyd ^a   Swingler, Tracey E ^a   Clark, Ian M ^a   Hemmings, Andrew M ^a   Chantry, Andrew ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Cancer; EMT; Smads; TGF ; Transcription; Ubiquitin ligase

Indexed keywords

SMAD PROTEIN; SMAD3 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; VIMENTIN; WWP2 UBIQUITIN LIGASE;

ARTICLE; CANCER STAGING; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; POINT MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; UBIQUITINATION; UPREGULATION;

EID: 84883501617     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.08.001     Document Type: Article

References (29)

1. Kerscher O., Felberbaum R., Hochstrasser M. Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu. Rev. Cell Dev. Biol. 2006, 22:159-180.
2. Navon A., Ciechanover A. The 26S proteasome: from basic mechanisms to drug targeting. J. Biol. Chem. 2009, 284:33713-33718.
3. Li W., Bengtson M.H., Ulbrich A., Matsuda A., Reddy V.A., Orth A., Chanda S.K., Batalov S., Joazeiro C.A. Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle's dynamics and signaling. PLoS One 2008, 3:e1487.
4. Ingham R.J., Gish G., Pawson T. The Nedd4 family of E3 ubiquitin ligases: functional diversity within a common modular architecture. Oncogene 2004, 23:1972-1984.
5. Rotin D., Kumar S. Physiological functions of the HECT family of ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 2009, 10:398-409.
6. Chantry A. WWP2 ubiquitin ligase and its isoforms: new biological insight and promising disease targets. Cell Cycle 2011, 10:2437-2439.
7. Soond S.M., Chantry A. How ubiquitination regulates the TGF-β signalling pathway: new insights and new players: new isoforms of ubiquitin-activating enzymes in the E1-E3 families join the game. Bioessays 2011, 33:749-758.
8. Maddika S., Kavela S., Rani N., Palicharla V.R., Pokorny J.L., Sarkaria J.N., Chen J. WWP2 is an E3 ubiquitin ligase for PTEN. Nat. Cell Biol. 2011, 13:728-733.
9. Soond S.M., Chantry A. Selective targeting of activating and inhibitory Smads by distinct WWP2 ubiquitin ligase isoforms differentially modulates TGFβ signalling and EMT. Oncogene 2011, 30:2451-2462.
10. Xu J., Lamouille S., Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009, 19:156-172.
11. Heldin C.H., Landström M., Moustakas A. Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr. Opin. Cell Biol. 2009, 21:166-176.
12. Wicks S., Haros K., Maillard M., Song L., Cohen R.E., ten Dijke P., Chantry A. The deubiquitinating enzyme UCH37 interacts with Smads and regulates TGFβ signalling. Oncogene 2005, 24:8080-8084.
13. Cutts A., Soond S., Powell S., Chantry A. Early phase TGFβ receptor signalling dynamics stabilised by the deubiquitinase UCH37 promotes cell migratory responses. Int. J. Biochem. Cell Biol. 2011, 43:604-612.
14. van de Wetering M., Oving I., Muncan V., Pon Fong M.T., Brantjes H., van Leenen D., Holstege F.C., Brummelkamp T.R., Agami R., Clevers H. Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep. 2003, 4:609-615.
15. Levy L., Hill C.S. Smad4 dependency defines two classes of TGF-{beta}-target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol. Cell. Biol. 2005, 25:8108-8125.
16. Nagarajan R.P., Zhang J., Lei W., Chen Y. Regulation of Smad7 promoter by direct association with Smad3 and Smad4. J. Biol. Chem. 1999, 274:33412-33418.
17. Liao B., Jin Y. Wwp2 mediates Oct4 ubiquitination and its own auto-ubiquitination in a dosage-dependent manner. Cell Res. 2010, 20:332-344.
18. Forbes S.A., Bhamra G., Bamford S., Dawson E., Kok C., Clements J., et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr. Protoc. Hum. Genet. 2008, 57:10.11.1-10.11.26.
19. Forbes S.A., Bindal N., Bamford S., Cole C., Kok C.Y., Beare D., Jia M., Shepherd R., Leung K., Menzies A., Teague J.W., Campbell P.J., Stratton M.R., Futreal PA P.A. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011, 39:D945-D950.
20. Mund T., Pelham H.R. Control of the activity of WW-HECT domain E3 ubiquitin ligases by NDFIP proteins. EMBO Rep. 2009, 10:501-507.
21. Chernoivanenko I.S., Minin An.A., Minin A.A. Role of vimentin in cell migration. Embryogenesis Carcinog. 2013, 44:186-202.
22. Wharton S.J., Basu S.P., Ashe H.L. Smad affinity can direct readouts of the embryonic extracellular Dpp gradient in Drosophila. Curr. Biol. 2004, 14:1550-1558.
23. Sutherland D.J., Li M., Liu X., Stefancsik R., Raftery L.A. Stepwise formation of a Smad activity gradient during ventral patterning of the Drosophila embryo. Development 2003, 130:5705-5716.
24. Wu Y., Zhang X., salmon M., Lin X., Zehner Z.E. TGFβ1 regulation of vimentin gene expression during differentiation during differentiation of the C2C12 skeletal myogenic cell line requires Smads, AP-1 and SP1 family members. Biochim. Biophys. Acta 2007, 1773:427-439.
25. Ju W., Ogawa A., Heyer J., Nierhof D., Yu L., Kucherlapati R., Shafritz D.A., Böttinger E.P. Deletion of Smad2 in mouse liver reveals novel functions in hepatocyte growth and differentiation. Mol. Cell. Biol. 2006, 26:654-667.
26. Petersen M., Pardali E., van der Horst G., Cheung H., van den Hoogen C., van der Pluijm G., Ten Dijke P. Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis. Oncogene 2010, 29:1351-1361.
27. Hoot K.E., Lighthall J., Han G., Lu S.L., Li A., Ju W., Kulesz-Martin M., Bottinger E., Wang X.J. Keratinocyte-specific Smad2 ablation results in increased epithelial-mesenchymal transition during skin cancer formation and progression. J. Clin. Invest. 2008, 118:2722-2732.
28. Javelaud D., Alexaki V.I., Mauviel A. Transforming growth factor-beta in cutaneous melanoma. Pigment Cell Melanoma Res. 2008, 21:123-132.
29. Ding Z., Wu C.J., Chu G.C., Xiao Y., Ho D., Zhang J., Perry S.R., Labrot E.S., Wu X., Lis R., Hoshida Y., Hiller D., Hu B., Jiang S., Zheng H., Stegh A.H., Scott K.L., Signoretti S., Bardeesy N., Wang Y.A., Hill D.E., Golub T.R., Stampfer M.J., Wong W.H., Loda M., Mucci L., Chin L., DePinho R.A. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011, 470:269-273.